---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-044932"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:07:18.703685+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics Q3 net loss widens to $5.1M; FDA clears NeuroNova IND

## Summary
- Net loss of $5.1M ($0.65/share) vs. $2.0M ($1.41/share) in Q3 2023.
- R&D expenses $2.2M, down from $3.3M; G&A $3.1M, down from $4.0M.
- Cash and restricted cash $2.1M as of Sept 30, 2024, unchanged from Dec 31, 2023.
- FDA cleared IND for NeuroNova (CLD-101) Phase 1b/2 trial in high-grade glioma; trial expected early 2025.
- Raised $2M in registered direct offering and private placement in October.

## SEC filing metadata
- accession: 0001493152-24-044932
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315224044932/0001493152-24-044932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315224044932/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-044932
- JSON: https://secwatch.observer/filing/0001493152-24-044932.json
- Plain text: https://secwatch.observer/filing/0001493152-24-044932.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.